Scripps (SNI) CEO Boehne Adopts Rule 10b5-1 Trading Plan
Tweet
Share
E-mailGet Alerts SNI Hot Sheet
Join SI Premium – FREE
Richard A. Boehne, president and CEO of The E.W. Scripps Company (NYSE: SSP), has adopted a stock trading plan in accordance with the guidelines specified by Rule 10b5-1 under the Securities Exchange Act of 1934.
Rule 10b5-1 permits corporate officers, directors and others to adopt written, pre-arranged stock trading plans when they are not in possession of material, non-public information. These plans allow insiders to have shares sold for their accounts over a period of time regardless of any material, non-public information they may receive after adopting their plans.
The sale of Scripps shares under these trading plans is intended to help diversify personal investment holdings.
Mr. Boehne's plan provides for the sale of approximately 382,000 shares (approximately 249,000 of which underlie exercisable options) if certain criteria are met. Sales may commence on May 8, 2013, and would be completed by March 28, 2014.
In accordance with 10b5-1 rules, Mr. Boehne will have no discretion over sales under his plan. All transactions under the plan will be disclosed through Form 144 and Form 4 filings with the Securities and Exchange Commission, as required by applicable securities laws.
Rule 10b5-1 permits corporate officers, directors and others to adopt written, pre-arranged stock trading plans when they are not in possession of material, non-public information. These plans allow insiders to have shares sold for their accounts over a period of time regardless of any material, non-public information they may receive after adopting their plans.
The sale of Scripps shares under these trading plans is intended to help diversify personal investment holdings.
Mr. Boehne's plan provides for the sale of approximately 382,000 shares (approximately 249,000 of which underlie exercisable options) if certain criteria are met. Sales may commence on May 8, 2013, and would be completed by March 28, 2014.
In accordance with 10b5-1 rules, Mr. Boehne will have no discretion over sales under his plan. All transactions under the plan will be disclosed through Form 144 and Form 4 filings with the Securities and Exchange Commission, as required by applicable securities laws.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Richard Lowenthal resigns from ARS Pharmaceuticals board
- Gyre Therapeutics adds three directors to its board
- Alpha Compute names Enzo Villani as president
Create E-mail Alert Related Categories
Corporate News, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
